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Abstract
Despite the ,10
18 ab T cell receptor (TCR) structures that can be randomly manufactured by the human thymus, some
surface more frequently than others. The pinnacles of this distortion are public TCRs, which exhibit amino acid-identical
structures across different individuals. Public TCRs are thought to result from both recombinatorial bias and antigen-driven
selection, but the mechanisms that underlie inter-individual TCR sharing are still largely theoretical. To examine this
phenomenon at the atomic level, we solved the co-complex structure of one of the most widespread and numerically
frequent public TCRs in the human population. The archetypal AS01 public TCR recognizes an immunodominant BMLF1
peptide, derived from the ubiquitous Epstein-Barr virus, bound to HLA-A*0201. The AS01 TCR was observed to dock in a
diagonal fashion, grasping the solvent exposed peptide crest with two sets of complementarity-determining region (CDR)
loops, and was fastened to the peptide and HLA-A*0201 platform with residue sets found only within TCR genes biased in
the public response. Computer simulations of a random V(D)J recombination process demonstrated that both TCRa and
TCRb amino acid sequences could be manufactured easily, thereby explaining the prevalence of this receptor across
different individuals. Interestingly, the AS01 TCR was encoded largely by germline DNA, indicating that the TCR loci already
comprise gene segments that specifically recognize this ancient pathogen. Such pattern recognition receptor-like traits
within the ab TCR system further blur the boundaries between the adaptive and innate immune systems.
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Introduction
Epstein-Barr virus (EBV), also called human herpesvirus 4
(HHV-4), is a genetically stable agent that has slowly co-evolved
with our species and its antecedents for millions of years. EBV is
typically transmitted orally during childhood, propagates in B cells
and epithelia, and is shed for the lifetime of the host. More than
90% of the world’s population is infected with EBV. This mutual
coexistence is not without heavy resource cost for the host. Large
populations of CD8
+ ab T lymphocytes are deployed for the
purposes of EBV surveillance and suppression. These populations
peak during asymptomatic primary infection [1], acute infectious
mononucleosis (AIM) [2] and old age [3]. Across the entire EBV
proteome, one of the most immunogenic CD8
+ T cell targets is the
HLA-A*0201-restricted GLCTLVAML peptide derived from the
BMLF1 protein (residues 280–288; herein referred to as GLC-A2).
During primary infection, up to 11% of the total peripheral CD8
+
T cell pool can be specific for GLC-A2 [4]; this response contracts
to 0.5–2.2% of the peripheral CD8
+ T cell pool during persistent
infection [4], but can swell again to 10% in old age [3]. Given the
high in vivo frequencies of this response and the ubiquity of both
EBV infection and the HLA-A*0201 allele, it is unsurprising that
GLC-A2 is one of the most studied HLA class-I target antigens.
Interestingly, initial investigations into the clonotypic nature of the
GLC-A2 response revealed that CD8
+ T cells are deployed with a
biased T cell receptor (TCR) repertoire [5,6,7,8] that is stable over
time [9].
The TCR is a clonotypic, membrane-bound receptor that binds
peptide-MHC (pMHC). Genetically, TCRs are rearranged into a-
and b-chains from a selection of 176 variable (V), diversity (D),
joining (J), and constant (C) genes on chromosomes 7 and 14.
Random recombination of these genes generates only 5–10% of
the potential diversity within the TCR repertoire; exonucleolytic
activity, random N nucleotide additions at the V(D)J junctions
[10] and ab chain pairing contribute the remainder. Theoretical
TCR diversity in humans has been placed in the region of 10
15–
10
20 unique structures [11,12,13], with direct in vivo estimates
greater than 2.5610
7 unique structures [14]. Structurally, TCR a-
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determining region (CDR) loops that can contact the pMHC
binding face. The germline-encoded CDR1 and CDR2 loops,
from the TRAV and TRBV genes, participate heavily in MHC
contacts and occasionally peptide contacts. The variable CDR3
loops, which span the V(D)J joints, are key to TCR diversity and
participate heavily in peptide contacts. TCRs dock with pMHC
complexes in a roughly diagonal fashion, such that the CDR3a
loops are placed over the peptide N-terminus and the CDR3b
loops lie over the peptide C-terminus.
In spite of the universe of TCR options available to the immune
system, some pMHC antigens provoke the emergence of biased
and predictable repertoires (reviewed in [15,16]). Accordingly, the
CD8
+ T cell response to the GLC-A2 antigen is seen to provoke
type III and type IV TCR bias. Type III bias is defined by
memory T cells bearing identical TCR receptor protein
sequences, often encoded by redundant codons, found between
individuals presenting a common pMHC antigen. Type IV bias is
defined by memory T cells bearing near identical TCR receptor
protein sequences, differing by only one or two residues in the
CDR3 loop, found between individuals presenting a common
pMHC antigen. GLC-A2-specific responses exhibit biased usage
of the TRBV20-1, TRBJ1-2, TRAV5, and TRAJ31 genes and
conserved CDR3 amino acid usage and length. We recently
undertook a large scale ex vivo TCR sequencing analysis (754
transcripts), as well as a meta-analysis, of the GLC-A2 response
and found that the most frequently shared (public) receptor
comprised the above genes with the CDR3a and CDR3b core
sequences CAEDNNARLMF and CSARDGTGNGYTF, respec-
tively [17].
In order to gain insight into the structural basis underlying the
emergence of this ubiquitous ab receptor, we solved the structure
of an archetypal GLC-specific TCR, derived from the CD8
+ T cell
clone AS01, in complex with the GLC-A2 antigen. In parallel, we
performed a detailed thermodynamic dissection of the complex
and identified key TCR contact hotspots via a biophysical
mutagenesis scan. To investigate the genetic basis behind the
dominant selection of the receptor, we performed computer
simulations of a random V(D)J recombination process to assess the
ease and frequency of manufacture. Herein, we describe the
structural and genetic basis for the dominance of the AS01 TCR
in EBV-infected humans.
Results
Overview of AS01-GLC-A2 complex
The structure of the AS01-GLC-A2 complex was determined to
a resolution of 2.54 A ˚ (Table 1). The final model had Rfree of
30.7% and Rcryst of 21.8%. The ratio, Rcryst/Rfree, falls within
the accepted limits shown in the theoretically expected distribution
[18]. The AS01 TCR was centrally perched on the GLC-A2
molecule over the exposed residues of the GLC peptide (Figure 1).
As illustrated in Figure 2A, AS01 bound in a canonically diagonal
fashion and was observed to dock at an angle of 41.7u,a s
calculated by the proposed TCR/pMHC crossing angle standard
[19]. This crossing angle falls within the range of previous human
TCR/pMHC class-I (pMHC-I) complexes (34u–80u, average
52.5u). The central residues of the GLC peptide bulged out from
the MHC surface in the classical fashion. Unusually, however, Leu
at residue P5, typically one of the most exposed regions of pMHC-
I 9-mer peptides, was pulled down into the MHC cleft, kinking the
backbone and making the adjacent residues, Thr at P4 and Val at
Author Summary
The human immune recombination machinery can gener-
ate approximately 10
18 unique ab T cell receptor
structures. The recombination event, once thought to be
random, has now been shown to involve enzymatic biases
during chromosomal rearrangement; additional biases
occur during thymic selection and antigen-driven expan-
sion in the periphery. The furthest extremes of these
collective biases result in public T cell receptors (TCRs),
defined as residue-identical receptors found across differ-
ent individuals who share a common major histocompat-
ibility complex (MHC) allele. One of the most prominent
public T cell responses found in humans is raised against
the GLCTLVAML (GLC) peptide from Epstein-Barr virus. We,
and others, have previously shown that a public TCR
constructed from the TRBV20-1/TRBJ1-2 and TRAV5/TRAJ31
gene segments dominates the GLC-specific repertoire.
Here, we investigate the genetic, biophysical and structural
forces that drive this public receptor, designated AS01,
with in silico estimates of relative production frequencies
during gene recombination, thermodynamic scanning and
crystallographic studies of the AS01-GLC-A2 complex. We
find that the TCRa and TCRb amino acid sequences of
AS01 are produced efficiently by a process of convergent
recombination and employ unique residues, encoded only
by the above-mentioned genes, to engage antigen in a
highly specific manner.
Table 1. Data collection and refinement statistics.
Parameters Value
Data set statistics
a
Space Group P21212
Unit Cell parameters (A ˚) a=94.1, b=122.5, c=82.4
Radiation Source DIAMOND I03
Wavelength (A ˚) 0.9763
Resolution (A ˚) 2.54 (2.61 – 2.54)
Reflection observed 251,677 (17,505)
Unique reflections 31,817 (2,222)
Completeness (%) 98.3 (93.4)
Multiplicity 7.9 (7.9)
I/Sigma(I) 12.2 (2.7)
Rmerge (%) 16.3 (83.2)
Refinement statistics
a
Measured Resolution Range (A ˚) 61.25 – 2.54
No reflections used 30,170 (2,105)
No reflections in Rfree set 1,603 (112)
Rcryst (no cutoff) (%) 21.8
Rfree (%) 30.7
Root mean square deviation from ideal geometry
b
Bond lengths (A ˚) 0.014 (0.021)
Bond Angles (u) 1.572 (1.936)
Mean residual B value after TLS (A ˚2) 14.866
Wilson B-factor (A ˚2) 43.1
Overall coordinate error (A ˚) 0.306
aValues in parentheses are for the highest resolution shell.
bValues in parentheses are target values.
N.B. One crystal was used for the full data set.
doi:10.1371/journal.ppat.1001198.t001
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and CDR1b/CDR3b loops were positioned on either side of the
exposed peptide residues at P4 and P6, clasping each side of the
peptide bulge (Figure 2C and 2D). The CDRa and CDRb loops,
as well as framework (FW) residues, shared in fastening the AS01
TCR to the MHC a-1 and a-2 helices (Figure 2E and 2F). A total
of 20 contacts were made at the TCR/pMHC interface,
comprising 4 peptide contacts and 16 MHC contacts (Table 2).
This is the second lowest number of contacts observed across all
human TCR/pMHC complexes to date [19,20,21,22]. However,
the total buried surface area (BSA) of the AS01-GLC-A2 complex
was 2134 A ˚ 2, which falls within the normal range of previous
human TCR/pMHC-I complexes (1471–2452 A ˚ 2, mean 1992 A ˚ 2)
(Table 3; Figure 2A).
Structural basis underlying AS01 selection
The CD8
+ T cell response to the GLC-A2 antigen exhibits
Type III and Type IV bias in vivo, with identical or near identical
TCRs within and between individuals [6,7,15,16,17]. The AS01-
GLC-A2 structure provides insight into the selection of this public
TCR. First, selection of the TRAV5 gene can be accounted for by
the presence of the Thr31-Try32 residue pair at the tip of the
CDR1a loop (Figure 2E). These residues fix AS01 to the MHC a-
2 helix via hydrogen bonds with Thr163 and with the mobile
‘gatekeeper’ Gln155 [23]. Engagement of the MHC a-2 helix is
further strengthened through FW residues within the TRAV5 gene-
encoded chain. Tyr49 and Lys69 can be seen to form a hydrogen
bond and salt bridge with Glu154 and Glu166, respectively
(Figure 2E). In addition, Tyr32 in the CDR1a loop also assists in
Figure 1. Overview of the AS01-GLC-A2 complex structure. (A) Ribbon representation of the AS01-GLC-A2 complex. The TCR a-chain and TCR
b-chain are depicted in light grey; CDR1a, CDR2a, CDR3a, CDR1b, CDR2b and CDR3b are depicted in green, red, blue, lime green, orange and aqua,
respectively. The HLA-A*0201 platform is depicted in light pink, with the stalk and b2-microglobulin in silver. The GLCTLVAML peptide is colored
orange and represented in ball-and-stick format. (B) Magnified view of the AS01-GLC-A2 complex interface from the same angle as in panel A. The
position of the AS01 TCR CDR loops over the central peptide bulge can be observed. For clarity, the MHC a-2 helix is omitted. (C) Magnified view of
the AS01-GLC-A2 complex interface at 90u clockwise rotation from panel B along the horizontal axis. The overall position of the AS01 TCR CDR loops
over both the MHC helices and the peptide can be observed.
doi:10.1371/journal.ppat.1001198.g001
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PLoS Pathogens | www.plospathogens.org 3 November 2010 | Volume 6 | Issue 11 | e1001198Figure 2. Interactions of the AS01-GLC-A2 complex. (A) Contact footprint of the AS01 TCR on the GLC-A2 surface. The HLA-A*0201 molecule is
surface represented and colored grey; the GLCTLVAML peptide is shown in ball-and-stick format and colored orange. The binding footprint over the
GLC-A2 surface of the AS01 TCR CDR1a, CDR2a, CDR3a, CDR1b, CDR2b and CDR3b loops are depicted in green, red, blue, lime green, orange and
aqua, respectively. The TCR/pMHC crossing angle is depicted in red. (B) Interactions governing anchoring of Leu5 to the MHC a-2 helix. The MHC cleft
is represented in ribbon format and the GLCTLVAML peptide, as well as the corresponding a-2 helix contacts, are represented in ball-and-stick format.
(C) Antigen-specific interactions between the AS01 TCR CDR1a loop (green sticks), the CDR3a loop (blue sticks) and the N-terminus of the
GLCTLVAML peptide. (D) Antigen-specific interactions between the AS01 TCR CDR1b loop (lime green sticks), the CDR3b loop (aqua sticks) and the C-
terminus of the GLCTLVAML peptide. (E) MHC (light pink sticks) interactions with the genetically unique components of the TCR a-chain framework
(FW) region (grey sticks) and CDR1 loop (green sticks). (F) MHC (light pink sticks) interactions with the genetically unique components of the TCR b-
chain FW region (grey sticks) and CDR2 loop (orange sticks). (G) Schematic representation of TCR and contacts (hydrogen bond, salt bridge or van der
Waals interactions) with peptide and the germline origins of the TCR contact residues. Only wholly non-germline encoded residues are depicted in
light grey. Asp93 is partially encoded by non-germline DNA.
doi:10.1371/journal.ppat.1001198.g002
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Thr4 (Figure 2C). Of the 47 TRAV genes available for
recombination, only the TRAV5 gene encodes a Thr-Tyr pair in
the CDR1a loop and only TRAV5 encodes Tyr49 and Lys69
within the FWa region. The germline origins of these peptide
contacts, as well as all TCR-peptide contacts, are shown in
Figure 2G. Second, selection of TRAJ31 over 56 other TRAJ gene
options can be accounted for by the presence of Arg97 and the
Asn94-Asn95 pair within the CDR3a core. The two Asn residues
form a structural arch that stabilizes the CDR3a loop above the
first peptide backbone hump residue at P4. Arg97 acts as a ‘‘hook’’
to stabilize the arch in a raised manner above Thr4. The raised
CDR3a lip allows Asp93 to lie precisely level with Thr4 to form a
hydrogen bond (Figure 2C). Only the TRAJ31 gene encodes the
Asn94, Asn95 and Arg97 pattern in the joining segment. Third,
selection of TRBV20-1 over the other 53 TRBV genes can be
accounted for by gene-specific interactions. Asn52 and Glu53 at
the tip of the CDR2b loop engage Gln72 and Arg75 of the MHC
a-1 helix, respectively, through a van der Waals interaction, a
hydrogen bond and a salt bridge (Figure 2F). Glu60, in the FWb
region, forms a salt bridge with Arg65 (Figure 2F). A peptide-
specific interaction is achieved via Thr32 in the CDR1b loop,
which engages Met8 through a van der Waals bond (Figure 2D).
Genetically, a small number of TRBV genes encode an Asn-Glu
pair in the CDR2b but only TRBV20-1 encodes both the CDR2b
Asn-Glu pair as well as FWb Glu60 and CDR1b Thr32. Fourth,
the importance of the contribution of the TRBD1 gene is
highlighted by the contacts made through Thr101, which is
TRBD1-encoded. Thr101 makes a hydrogen bond with Met8 of
the peptide (Figure 2D). Finally, selection of TRBJ1-2 over the
other 12 TRBJ gene options can be accounted for by the Tyr105-
Thr106 pairing in the CDR3b loop terminus. Tyr105 forms a
hydrogen bond with Arg98, found at the beginning of the CDR3b
sequence. This internal brace stabilizes the entire loop structure. It
is of particular interest that only the TRBV20-1 gene encodes Arg
at this position. Thr106 also has an important internal structural
Table 2. Contacts between AS01 TCR and GLC-A2.
TCR region TCR residue MHC residue Bond type
a Distance
CDR1a Thr31 OG1 Thr163 OG1 HB 2.81
Try32 OH Gln155 O HB 3.12
FWa Tyr49 OH Glu154 OE1 HB 3.16
Lys69 NZ Glu166 OE1 SB 3.15
Lys69 NZ Glu166 OE2 SB 3.04
CDR3a Asn95 ND2 Gly62 CA vdW 3.39
Arg97 NH1 Glu60 OE1 SB 2.66
Arg97 NH1 Arg65 NH1 vdW 3.26
Arg97 NH1 Arg65 NH2 vdW 3.36
Arg97 NH1 Arg65 CZ vdW 3.28
CDR2b Asn52 ND2 Gln72 CD vdW 3.28
Glu53 OE1 Arg75 NH1 SB 2.51
Glu53 O Arg75 NH2 HB 2.48
FWb Glu60 OE2 Arg65 NH1 SB 3.10
CDR3b Asn103 ND2 Ala150 O HB 2.94
Asn103 ND2 Gln155 OE1 HB 2.65
TCR residue Peptide residue
CDR1a Tyr32 CE2 Thr4 OG1 vdW 3.36
CDR3a Asp93 OD1 Thr4 OG1 HB 2.74
CDR1b Thr32 CG2 Met8CE vdW 3.33
Asn103 N Val6 O HB 3.00
aBond type defined as a hydrogen bond (HB), salt bridge (SB) or van der Waals
(vdW).
doi:10.1371/journal.ppat.1001198.t002
Table 3. Analysis of human TCR/pMHC-I complexes.
TCR PDB MHC Peptide BSA
a Affinity
b SC total
c
SC TCR/
MHC
d
SC TCR/
Peptide
e Peptide contacts
f Reference
B7 1BD2 A*0201 LLFGYPVYV 1697 NT 0.643 0.597 0.798 60 [75]
A6 1AO7 A*0201 LLFGYPVYV 1816 2.0 0.632 0.642 0.640 47 [75]
JM22 1OGA A*0201 GILGFVFTL 1471 5.6 0.635 0.698 0.610 29 [48]
LC13 1MI5 B*0801 FLRGRAYGL 2020 10.0 0.612 0.599 0.659 28 [47]
1G4 2BNR A*0201 SLLMWITQC 1916 13.3 0.717 0.604 0.837 110 [76]
SB27 2AK4 B*3508 LPEPLPQGQLTAY 1752 9.9 0.715 0.594 0.825 65 [23]
DM1 3DX8 B*4405 EENLLDFVRF 2200 NT 0.595 0.536 0.763 37 [22]
MEL5 3HG1 A*0201 ELAGIGILTV 2452 18.0 0.625 0.575 0.763 29 [21]
ELS4 2NX5 B*3501 EPLPQGQLTAY 2400 NT 0.686 0.647 0.768 39 [77]
RA15 3GSN A*0201 NLVPMVATV 2200 6.3 0.631 0.607 0.732 5 [20]
AS01 3O4L A*0201 GLCTLVAML 2134 8.1 0.640 0.676 0.577 4 -
aBuried surface area (A ˚2) at the TCR/pMHC interface.
bBinding affinity (KD)i nmM.
cTotal shape complementarity index between the TCR and pMHC-I molecule.
dShape complementarity index between the TCR and MHC-I molecule.
eShape complementarity index between the TCR and peptide.
fTotal number of hydrogen bonds, salt bridges and van der Waals force contacts between TCR and peptide within 3.4A ˚.
NT: Not tested.
Note: BSA, KD, and peptide contacts previously published in the final table column reference as well as [19].
doi:10.1371/journal.ppat.1001198.t003
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interaction with Phe29 of the CDR1b. It is of additional note that
only TRBV20-1 encodes Phe at this position when compared to all
available 54 CDR1b loops. To conclude, only TRBJ1-2 encodes a
Tyr-Thr pair within the joining gene area, underlying its genetic
preference associated with TRBV20-1 in the public receptor.
Binding affinity and thermodynamics of the AS01-GLC-A2
complex
To complement information gained from the crystal complex,
we dissected in detail the affinity and thermodynamics of the
public AS01 TCR. To achieve this, the binding strength of the
AS01-GLC-A2 complex was measured at 5, 12, 19, 25 and 37uC
using surface plasmon resonance (SPR). At 25uC, the KD of the
complex was 8.1 mM (Figure 3; Figure S1). This baseline affinity
falls within the range of previously published human TCR/
pMHC-I complexes (0.1–100 mM) and is typical of human TCR/
pMHC-I complexes from viral systems (0.1–21 mM) [19,24,25]
(Table 3). Interestingly, we observed that the affinity of the AS01-
GLC-A2 complex interaction decreased with increasing temper-
atures; thus, KD values gradually decreased from 4.7 mMa t5 uCt o
16.7 mMa t3 7 uC (Figure 3A–G). This difference was mainly due
to a much faster off-rate (Koff) at higher temperatures (Koff =1.2
sec
21 at 37uC compared to 0.15 sec
21 at 5uC) (Figure 3H). Thus,
at physiological temperature (37uC), the AS01 TCR binds with
weaker affinity than at the standard measurement temperature
(25uC). This difference may impact the antigen sensitivity of CD8
+
T cells bearing this public receptor in vivo.
The affinity of an interaction can be represented as its binding
free energy, DGu (DGu=-RTlnKD). This binding energy is the
sum of enthalpic (DH) and entropic (2TDS) components as
calculated using the Gibbs-Helmholtz equation (DGu=DH 2
TDSu), either of which can be favourable (act to increase the
affinity) or unfavourable (act to decrease the affinity). The binding
of proteins is also accompanied by a change in the heat capacity
DCpu. In order to calculate DHu,T DSu and DCpu, the binding
constant data were subjected to van’t Hoff analysis by plotting the
binding DGu versus temperature (K) using nonlinear regression to
fit the three-parameter equation to the curve (see Materials and
Methods). The AS01-GLC-A2 interaction was characterized by a
binding DGu of 26.9 kcal/mol at 25uC (the standard for
measuring TCR/pMHC parameters [26]), which is within the
normal range for TCR/pMHC interactions [27]. The energy of
the interaction was probably derived primarily from a net increase
in the formation of new noncovalent bonds (hydrogen bonds, salt
bridges and van der Waals contacts) during complex formation,
evident from the favorable enthalpy (DHu=28.8 kcal/mol).
Notably, this TCR/pMHC interaction is entropically unfavour-
able (TDSu=21.9 kcal/mol), although this value lies at the lower
end of the scale of published TCR/pMHC entropic values (20.4
to 229 kcal/mol) [27]. The relatively small DCpu value of 20.4
kcal/mol?K is within the range of other TCR/pMHC complexes
[27] (Figure 3G), which conforms with the normal SC value for
this complex. Next, we investigated the thermodynamic properties
of the AS01-GLC-A2 complex at the physiologically relevant
temperature of 37uC. At this temperature, the binding free energy
(DGu=26.8 kcal/mol) was very similar to the binding energy
observed at 25uC( DGu=26.9 kcal/mol). However, at 37uC, the
interaction was driven strongly by enthalpy, evident from the
decrease in DHu to 214.1 kcal/mol (37uC) (Figure S3). This
resulted in a larger entropic cost to complex formation
(TDSu=27.3 kcal/mol). Thus, at 37uC, the interaction between
the AS01 TCR and GLC-A2 is more enthalpically driven, with a
greater entropic penalty, compared to 25uC.
Verification of TCR binding hot spots
The AS01-GLC-A2 structure indicated that Thr4, Val6 and
Met8 of the peptide are important for TCR docking. Indeed, the
AS01 TCR contacts only these residues in the peptide. To verify
the importance of these contact areas, we performed an Ala
mutagenesis scan across the peptide backbone and evaluated the
capacity of the pMHC-I mutants to bind the AS01 TCR using
SPR (Figure 4; Figure S2). As peptide positions P1, P2 and P9 are
often buried and/or important for MHC binding, we focused on
assessing the solvent exposed positions P3, P4, P5, P6 and P8. We
did not assess P7, as this residue is Ala in the native sequence. As
expected, given that no contacts were made with Cys3, mutation
of P3 had a relatively small effect on TCR binding (,5-fold
reduction) (Figure 4). Conversely, mutation of Thr4 reduced AS01
TCR binding by more than 60-fold to 685.2 mM, presumably
through loss of two side-chain contacts provided by the CDR1a
and CDR3a loops. Interestingly, mutation at Leu5 resulted in a
,17-fold reduction in affinity to 177 mM. While Leu5 is not a
TCR contact residue, it does affect the total peptide backbone
structure by providing a secondary anchor that results in a kink in
the centre of the peptide backbone. This kink, made via hydrogen
bonds with main chain atoms of Val152 and Leu156 of the MHC
a-1 helix, pulls Leu5 into the MHC groove. In this conformation,
Thr4 and Val6 form two ‘‘humps’’ on either side of Leu5. The
mutation of Leu5 to Ala would probably result in the loss of this
MHC anchoring and allow the peptide backbone to relax in the
cleft. This backbone loosening would likely push Thr4 and Val6
into new conformations, resulting in the loss of original contacts.
As expected, mutation of TCR contact residue Val6 resulted in a
considerable reduction in affinity to 133.8 mM( ,13-fold). This
affinity reduction is likely caused by the loss of two non-polar
interactions between the Val6 side-chain atoms and the CDR3b
loop. Finally, mutation of Met8 reduced the affinity of AS01 TCR
binding to 43.9 mM. This modest effect can likely be explained by
the loss of a single, side-chain-derived van der Waals bond with the
CDR1b loop. The original hydrogen bond, formed by the CDR3b
and the main-chain atoms of Met8, would likely remain when
Met8 is mutated to Ala.
Surface complementarity (SC) preference of the AS01
TCR
The SC program, from the CCP4 suit [28], is able to index the
binding potential of two molecules between 0.0 (no SC) and 1.0
(perfect SC). As well as overall SC, SC indices can be partitioned
to different zones of the contact face. This can help specify where
two molecules invest the bulk of their contact energies. We
calculated the SC of the AS01 TCR between: (i) the whole GLC-
A2 molecule; (ii) just the HLA A*0201 molecule; and, (iii) just the
peptide (Table 3). We also extended this SC assessment to a full
meta-analysis of all conventional human TCR/pMHC-I com-
plexes solved to date (Table 3). Alloreactive structures were
omitted from the meta-analysis. This review also included BSA
and binding affinities of the complex set, as well as the number of
contacts made between TCR and peptide within 3.4A ˚. The AS01-
GLC-A2 complex exhibited a SC index of 0.640, which is average
for TCR/MHC-I complexes (mean=0.648). Interestingly, while
the total pMHC-I SC appeared typical, the AS01 TCR revealed a
SC preference for MHC-I (SC=0.676) over peptide (SC=0.577).
The large majority of TCR/MHC-I complexes studied thus far
reliably exhibit a higher SC index for peptide compared with
MHC. In fact, only the JM22 TCR joins AS01 in this unusual,
large-scale switch of region preference.
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PLoS Pathogens | www.plospathogens.org 6 November 2010 | Volume 6 | Issue 11 | e1001198Figure 3. Binding affinity and thermodynamics of the AS01-GLC-A2 interaction. SPR measurements were conducted at different
temperatures as shown. Ten serial dilutions of the AS01 TCR were measured in triplicate at each temperature; the mean response for each
concentration is plotted. (A-F) The equilibrium binding constant (KD) values were calculated in each case using a nonlinear curve fit (y=( P 1x)/P2 + x));
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Along with obvious structural features that promote AS01
selection, underlying genetic factors are likely to exist that elevate
the frequency at which this receptor is manufactured. We have
previously identified a process of convergent recombination that
may enable some TCRs to be produced more efficiently than
others [29]. Using computer simulations of a random V(D)J
recombination process we have demonstrated for numerous
systems [17,30,31] that convergent recombination leads to large
differences in TCR production frequencies, even in the case of
completely unbiased gene recombination. These simulations
account for the various mechanisms that contribute to the
production of TCR nucleotide and amino acid sequences,
including TRV, TRD and TRJ gene splicing, N nucleotide
additions, recurrent CDR3 motifs and codon redundancy. We
have previously shown that the public TCR b-chain (TRBV20-1/
CSARDGTGNGYTF/TRBJ1-2) is the most common chain used
in vivo in the GLC-specific response and is the second most
frequent GLC-A2-specific TRBV20-1/TRBJ1-2 chain made in
silico by random gene recombination [17]. We have expanded this
TCR b-chain analysis to include additional published clonotypes
[6,7] and confirm our previous results here (Figure 5C–D). In
addition, we simulated the production of TCR a-chains using the
TRAV5 and TRAJ31 genes to assess the relative production
frequencies of GLC-A2-specific TCR a-chain sequences based on
previously identified in vivo clonotypes [6,7]. The simulation
indicated that the public TCR a-chain (TRAV5/CAEDN-
NARLMF/TRAJ31) is the most efficiently produced TRAV5/
TRAJ31 combination in the GLC-A2 response (Figure 5A–B),
being generated ,6 times more frequently in silico than the next
most efficiently generated clonotype CAEIHARLMF. Aiding the
ease of production, both the public TCR a- and b-chain amino
acid sequences can be encoded by nucleotide sequences requiring
few N nucleotide insertions The AS01 b-chain contains just 4 N
nucleotide insertions, with only Asn103 being randomly encoded
(Figure 5E). Furthermore, the AS01 TCR b-chain can been
observed in vivo to be manufactured with just two N nucleotide
additions (Figure 5F) [17]. The AS01 TCR a-chain contains just a
single N nucleotide insertion, partially encoding Asp93.
Discussion
The archetypal AS01 TCR is likely to be one of the most
common and numerically frequent ab TCRs in humans. This is
based on the following considerations: (i) the HLA-A*0201 allele is
arguably the most common and widespread MHC-I allele in
Figure 4. Binding affinities of the AS01 TCR with GLC-A2 variants. Equilibrium binding analysis at 25uC for wildtype GLC peptide (A) and
alanine mutants (B-F). Ten serial dilutions of the AS01 TCR were measured in triplicate for each equilibrium experiment; the mean response for each
concentration is plotted. The equilibrium binding constant (KD) values were calculated using a nonlinear curve fit (y=( P 1x)/P2 + x)) as previously
reported [24,26,37]; mean plus SD values are shown.
doi:10.1371/journal.ppat.1001198.g004
mean plus SD values are shown. (G) The thermodynamic parameters were calculated according to the Gibbs-Helmholtz equation (DGu=DH 2 TDSu).
The binding free energies, DGu (DGu=-RTlnKD), were plotted against temperature (K) using nonlinear regression to fit the three-parameter equation,
(y=dH+dCp*(x-298)-x*dS-x*dCp*ln(x/298)), as previously reported [69]. (H) AS01 TCR (18.1 mM) was injected over GLC-A2 at 5, 12, 19, 25, 32 and 37uC.
The responses observed with injections of AS01 TCR over a control sample were deducted. Off-rates (Koff) were calculated assuming 1:1 Langmuir
binding using a global fit algorithm (BIAevaluate 3.1). Data and fits are shown.
doi:10.1371/journal.ppat.1001198.g003
A Common TCR in EBV Infection
PLoS Pathogens | www.plospathogens.org 8 November 2010 | Volume 6 | Issue 11 | e1001198Figure 5. Convergent recombination analysis of the AS01 TCR. Previously reported TRAV5/TRAJ31 (A) and TRBV20-1/TRBJ1-2 (C) amino acid
clonotypes specific for the GLC-A2 epitope are listed together with the number of individuals in which each clonotype was observed. Sequences
were mined from previous studies A [8,17], B [7] and C [6]. To assess the role of convergent recombination and TCR production frequency in the inter-
individual sharing of these TRAV5/TRAJ31 and TRBV20-1/TRBJ1-2 amino acid clonotypes, computer simulations of a random V(D)J recombination
process involving either the TRAV5/TRAJ31 or TRBV20-1/TRBJ1-2 gene combinations were used to estimate their relative production frequencies. The
number of times that each observed GLC-specific TCR amino acid sequence was generated in the simulations of a random V(D)J recombination
process is shown for the TRAV5/TRAJ31 (B) and TRBV20-1/TRBJ1-2 (D) amino acid clonotypes versus the number of individuals in which each
sequence was observed. The solid horizontal lines represent the medians of the number of times that TCR sequences observed in a particular number
of individuals were simulated. The dashed horizontal lines extending the width of the plots represent the mean frequency of sequence generation,
across all observed GLC-specific TRAV5/TRAJ31 or TRBV20-1/TRBJ1-2 amino acid clonotypes, regardless of the number of individuals in which they
were found. The data shown for the TRBV20-1/TRBJ1-2 clonotypes have been published previously [17] and are shown here for completeness.
a Four
TRB clonotypes could not be made with the parameters used in the simulation; these are not included in panel D. The most shared GLC-specific TCRa
amino acid clonotype (TRAV5/CAEDNNARLMF/TRAJ31) was encoded by 18 different nucleotide sequences and produced by a total of 117 different
recombination mechanisms (i.e. different splicings of the germline genes and nucleotide additions) in the simulations. The most shared GLC-specific
TCRb amino acid clonotype (TRBV20-1/CSARDGTGNGYTF/TRBJ1-2) was encoded by 16 different nucleotide sequences and produced by a total of 47
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EBV is one of the most successfully disseminated human
pathogens, persistently infecting more than 90% of individuals
[33]; (iii) the GLC-A2 antigen is one of the most immunodominant
CD8
+ T cell targets across the EBV proteome [4]; (iv) GLC-
specific CD8
+ T cell responses are amongst the largest observed,
both in the EBV system and in comparative terms with respect to
other human pathogens studied thus far [4]; and, (v) the GLC-
specific response is dominated by CD8
+ T cells that bear a public
TRAV5/TRBV20-1 receptor [17].
Structurally, most features exhibited by the AS01 TCR are
within the parameters previously seen in the TCR/pMHC-I
system [19]. AS01 docks in a roughly diagonal fashion to the
pMHC and is positioned centrally above the peptide. The TCR a-
chain is positioned above the peptide N-terminus and the TCR b-
chain is positioned above peptide C-terminus. The peptide is
engaged chiefly by the CDR3 loops with additional support from
the CDR1 loops. AS01 interacts with the MHC helices via
residues within the CDR1 and CDR2 loops, which include bonds
with universal MHC anchors Arg65 and Gln155. Gln155 is
proposed to be a ‘‘gatekeeper’’ residue guiding MHC-I-restricted
TCR recognition as it is universally contacted by all ab TCRs
studied to date and often switches conformation between bound
and unbound forms [23,34]. Interestingly, however, the AS01
TCR does not contact Arg69, which represents the third member
of the classical MHC ‘‘restriction triad’’ [34]. Biophysically, the
AS01 TCR binds GLC-A2 with a KD of 8.1 mM, which is typical
for TCR interactions with viral MHC-I-restricted antigens
[19,24]. The AS01-GLC-A2 complex also has an average BSA
(of 2134 A ˚ 2) that is within, if not towards the higher end, of the
TCR/pMHC system. One notable structural trait of the AS01
TCR is its SC preference. The large majority of TCR/pMHC-I
complexes have a peptide.MHC SC bias. This bias is inverted in
the AS01-GLC-A2 complex. Again, interestingly, only the JM22
TCR, which is also public and HLA-A*02-restricted, exhibits this
inverted preference. Ultimately though, this particular trait cannot
be exclusively assigned to public TCRs since the RA15 and LC13
TCRs show conventional SC preference.
Thermodynamic analysis revealed that the interaction between
the AS01 TCR and GLC-A2 was within the normal range of other
reported TCR/pMHC interactions [27]. Importantly, the inter-
action was strongly enthalpically driven; thus, stabilization of the
TCR/pMHC interface through the formation of noncovalent
bonds is likely to be the chief factor driving complex formation. In
addition, the complex exhibited unfavourable entropy, indicating
that there was a net gain of order during TCR/pMHC binding.
This observation indicates that the entropic energy generated by
expulsion of solvent (ordered water molecules) upon complex
formation is countered by the entropic energy penalty attributed to
the conformational ordering of the TCR CDR loops and pMHC
surface during docking. These data are in agreement with previous
thermodynamic analyses of TCR/pMHC interactions, which
show that the favorable enthalpic energy generated by the
formation of a relatively large number of new contacts at the
interface is countered by a large unfavorable entropic cost that
results in a relatively weak binding affinity compared to other
protein-protein interactions [27,35,36,37]. Lastly, we investigated
the thermodynamic properties of the AS01-GLC-A2 complex at
the physiologically relevant temperature of 37uC. Notably, at
37uC, the interaction between the AS01 TCR and GLC-A2 was
more strongly enthalpically driven, with a greater entropic penalty,
compared to 25uC. Importantly, these differences in binding
energy almost halved the affinity of AS01 TCR binding at 37uC
compared to the standard measurement temperature of 25uC.
Kinetic analysis revealed that the reduction in binding affinity was
primarily attributed to a much faster off-rate at higher temper-
atures (Figure 3H). Thus, the AS01 TCR appears to bind less
optimally to GLC-A2 at physiological temperatures (37uC)
compared with the standard temperature used for SPR measure-
ments in vitro (25uC).
The mutagenesis scan across the GLC peptide highlighted a
number of critical zones for TCR recognition. As expected,
mutation of the prominent peptide hump residues, Thr4 and
Val6, resulted in 10–70 fold loss in affinity. A relatively surprising
finding was the 17-fold loss in affinity following mutation of Leu5.
Leu5 is not involved in TCR contacts and points down into the
MHC cleft. Leu5 does, however, act as a secondary anchor for the
GLC peptide, reinforcing the peptide backbone. Loss of this
reinforcement would likely result in the peptide backbone
‘sinking’ into the MHC cleft, producing a less interactive
interface. Recently seen in other systems [38], this observation
highlights the importance of peripheral residues in TCR
engagement. A note of broader interest is that every mutation
along the GLC peptide resulted in a reduction of affinity (40 mM
and above), whether within a TCR contact zone or not. TCRs
specific for class-I-bound antigens of viral origin typically operate
in the KD ,10 mM range and none have been seen over 30 mM
[24]. Thus, a mutation at any of these points could result in
suboptimal engagement with the archetypal public TCR. This
would likely result in either the public TCR being outcompeted
by higher affinity options in vivo or a hole in the TCR repertoire
and possibly a reduction in immunogenicity. Interestingly, there is
no evidence that EBV attempts to escape from the GLC response,
as seen by complete epitope conservation across all known strains
and isolates (GeneBank). This is remarkable given the consider-
able genetic variation between EBV strains [39,40] and within
some T cell epitopes [41,42,43,44]. It is certainly conceivable that
EBV has at least some flexibility to mutate the GLC backbone
without a significant loss of viral fitness. Hence, a question
presents itself. Why does EBV not try to escape from one of the
most potent T cell responses raised against it? In assessing this
question, it is important to note that genetic evidence from EBV
studies suggests that evolutionary pressure on T cell epitopes is
directed towards their conservation rather than their inactivation
[45]. This leads to speculation that epitope conservation may be
advantageous to the virus. Thus, some highly immunogenic
epitopes could be maintained deliberately to elicit large fleets of
CD8
+ T cells, perhaps to regulate viral replication, minimize
pathology and maintain a peaceful coexistence with the host.
Alternatively, the large T cell responses generated by these
epitopes may aid the virus as bonus replicative tissue. In addition
to the well established tropic tissues, B cells and epithelia, EBV
has recently been found in several human tissues including T cells
[46]. A related question is whether TCR affinity influences
epitope variation. The affinity of the AS01 TCR, at physiological
temperature, is in the lower half of the range reported for anti-
viral TCRs to date [24]. Could this small decrease in relative
affinity place less selection pressure on the GLC epitope? This is
different recombination mechanisms. The CDR3 nucleotide sequences coding for the AS01 TCR (E) and the CDR3 nucleotide sequences coding for the
most shared TCRa and TCRb amino acid clonotypes in the GLC-specific response (F). The corresponding TRBV, TRAV, TRBD, TRBJ and TRAJ genes are
listed. Germline-derived nucleotides are highlighted in grey and non-germline-derived nucleotides are bolded and underlined.
doi:10.1371/journal.ppat.1001198.g005
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intrinsic mutagenic potential of the epitope.
Genetically, the public AS01 TCR is primarily assembled from
chromosome-derived DNA (Figure 5E). The TCR b-chain and
TCR a-chain incorporate just 4 and 1 non-germline nucleotide/s,
respectively. Only one residue in the receptor (Asn103b)i s
encoded wholly by non-germline DNA. Interestingly, in many
individuals, Asn103b in the AS01 TCR is majority encoded by the
TRBJ1-2 gene (Figure 5F) [17]. Thus every residue in the AS01
TCR can be wholly or partially encoded by germline DNA. This
‘‘germline-rich’’ feature of the TCR a-chain and TCR b-chain
amino acid sequences of AS01 contributes towards the prediction
that these are frequently produced by convergent recombination
[30]. The public AS01 TCR comprises the TRBV20-1, TRBD1,
TRBJ1-2, TRAV5 and TRAJ31 genes. Structural analysis revealed
that each of these TR genes encode unique residue patterns that
appeared specialized for the GLC-A2 ligand. Critical docking
residues, found within the TCR/pMHC interface, were exclu-
sively encoded by the TR genes listed above and were not resident
in the other 168 genes available on the TCR a and b loci. Thus,
this specific structural architecture required to preserve the AS01
docking mode explains the TRBV, TRBJ, TRAV, and TRAJ bias
in the GLC-A2 CD8
+ T cell response.
The AS01-GLC-A2 complex necessitates comparison with
other published public TCR structures including the LC13 TCR
[47] and the JM22 TCR [48]. The LC13 TCR is specific for the
FLRGRAYGL (FLR) peptide from EBV and restricted by the
HLA-B*0801 molecule. The LC13 TCR, composed of TRBV7-8/
TRBJ2-7 and TRAV26-2/TRAJ52 gene products, is residue-
identical between individuals (Type III bias) [49,50,51]. Intrigu-
ingly, the LC13 TCR is also heavily comprised of germline DNA.
The TCR b-chain can be constructed wholly from germline DNA
[49,50,51]. The TCR a-chain shows a similar degree of germline
composition and only a single residue (Pro93) is encoded by DNA
of non-germline origin. The TCR/pMHC complex reveals that
the LC13 TCR engages its cognate ligand at a crossing angle of
42u [47], virtually identical to that of AS01. Also akin to AS01, the
contact footprint was evenly split between the TCR a- and b-
chains. The LC13 TCR was seen to adjust conformation during
ligation, manoeuvring its CDR3 loops around two central solvent
expose residues at P6 and P7. The AS01 TCR also engaged
central residues of the peptide; however, it is unknown whether
AS01 also undergoes conformational change upon ligation, as this
would require the TCR structure in an unligated state. A
structural basis underlying the selection of LC13 TCR was
evident upon examination of the complex. Contact residues
exclusively encoded by the constituent genes were critical for
specific engagement [47], and mutation of these germline-encoded
residues abrogated recognition [50]. Overall, the LC13 and AS01
TCRs exhibit close genetic and structural parallels. However, the
investment of germline DNA composition alternates between the
receptors. Thus, the LC13 TCR exhibits more germline
composition on the b-chain compared with the a-chain. This
pattern is inverted in the AS01 TCR. It is also worth noting that
the HLA-B*0801 allele, to which the LC13 TCR is restricted, is
arguably the most common HLA-B allele in Caucasian popula-
tions. The JM22 TCR is specific for the GILGFVFTL (GIL)
peptide from the influenza virus and is restricted by the HLA-
A*0201 molecule. In this response, gene bias is skewed to TRBV19
with a common Arg residue in the CDR3b loop [52,53]. However,
in contrast to the GLC- and FLR-responses, the GIL-specific
repertoire is more variable and identical TCRs are not always
apparent across individuals. A number of different TRBJ genes are
used in the repertoire along with variation in CDR3b residue
composition and CDR3b length [52,53]. The paired TCR a-
chain is also variable, with fluctuation in TRAV gene usage. In
general, the GIL-specific response is an example of Type IV bias.
The TCR/pMHC complex revealed that JM22 engages its
cognate ligand at a crossing angle of 62u [48], which is more
orthogonal compared with AS01. As suggested by the above
mentioned gene bias, the contact footprint is considerably ‘‘b-
centric’’, with residues within the TRBV19-encoded CDR1 and
CDR2 loops dominating pMHC engagement. This docking
modality allowed the conserved Arg in the CDR3b loop to peg
the TCR between the peptide and MHC groove. A detailed
mutational analysis revealed that germline-encoded residues were
critical for antigen specificity and, along with CDR3b Arg peg, it
was hypothesized that the TRBV19 gene may have been
evolutionary useful during recurrent influenza pandemics [54].
The germline-rich composition of the AS01 TCR draws
parallels with the TCRs displayed by iNKT cells from the innate
immune compartment. Here, the iNKT TCR a-chain (TRAV10/
TRAJ18) can be manufactured wholly by germline DNA [55].
Structural analysis of an iNKT TCR bound to its cognate CD1d-
a-GalCer ligand revealed that the receptor docks in a parallel
fashion to the antigen cleft [56], a docking modality very different
to the diagonal docking of AS01 and the other MHC-restricted
receptors [19]. In this parallel docking mode, the CDR1a and
CDR3a loops were seen to dominate the contact footprint across
both CD1d and the antigen; the residues involved in these contacts
were exclusively encoded by the TRAV10 and TRAJ18 genes,
providing a structural basis for invariant gene bias. A further
mutational study across the iNKT TCR confirmed the critical
importance of these germline-encoded CDR1a and CDR3a
residues for ligand recognition [57]. These studies reinforce the
observation that extreme biases within TCR repertoire formation
are likely shaped through highly specific structural requirements of
the target ligand. The iNKT TCR differs from the AS01 TCR in
that it that has an unprecedentedly small BSA (of 910A ˚ 2), likely as
a result of the a-chain binding towards the terminus of the binding
cleft. This binding mode pushes the b-chain towards the extreme
end of the binding cleft and limits its role during engagement
[56,58], providing a structural basis for the highly diverse nature of
the iNKT b-chain repertoire in vivo [55]. Conversely, the AS01
TCR a- and b-chains are both public, and the contact footprint is
more evenly spread across both chains.
EBV has engaged our species and its antecedents for
approximately 80 million years [59]. During this entwined co-
evolution, countless immune assaults and counter-assaults would
have been waged, with many genes formed and lost. Natural
selection and hereditary transmission would have progressively
bestowed useful genes for host defence and virus offence. It is likely
that the 450 million year old combinatorial immune system [60],
and more specifically the highly polymorphic TCR and MHC
gene set, would have been intimately involved in this ‘‘arms race’’.
Thus, it is conceivable that public TCRs, such as AS01, may be
very old defence structures, easily formed and found on the
chromosome, that provide a naive pre-emptive defence net against
almost-certain infection by primordial pathogens. Conversely, it
could be argued public TCRs are simple by-products of biases in
the V(D)J recombination system, according to which some
receptor combinations leave the thymus more often than others.
In conflict with this straightforward genetic hypothesis is the
observation that some public TCRs exist with the same amino acid
CDR3 sequences that are redundantly encoded by largely non-
germline derived DNA [49]. This indicates that, during compet-
itive antigen-driven selection, there is some structural advantage
already encoded in the original germline sequence. That is, we
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chromosome that are exquisitely specific for EBV targets. Given
the time scale of this conflict, it is intriguing to consider whether
public TCRs have evolved to aid the host or EBV itself; perhaps
they could even represent some middle ground that favours a
largely peaceful coexistence? Ultimately though, the role of
evolution in guiding this phenomenon is unknown and can only
be conjectured. After all, these TRBV and TRAV gene segments
are likely useful in defence against other pathogens. In addition,
TCR variable genes appear to have an innate preference for
MHC [61], so the idea of a germline receptor having both highly
tuned specificity and broad cross-reactive potential is, while not
strictly mutually exclusive, an interesting observation. Aside from
the origins of the public receptor phenomenon, the AS01-GLC-A2
complex may provide a fascinating glimpse of an ancient immune
battle, fought quietly and in the same way, possibly billions of
times across the two hundred thousand years of homo sapiens history
[62].
Materials and Methods
T cell clone generation and TCR isolation
The AS01 CD8
+ T cell clone was generated from a healthy
EBV
+, HLA-A*0201
+ individual as described previously [63].
Briefly, PBMC were stimulated with 1 mM GLCTLVAML
peptide and cloned via limiting dilution. The AS01 TCR was
identified as described previously [64]. Briefly, total RNA was
extracted from 10
5 T cells using TRIzol reagent and a RT-PCR
was performed using Superscript III (Invitrogen Life Technolo-
gies). PCR was performed using a panel of TRAV- and TRBV-
specific primers and the product was cloned into the pGEM-T
vector system (Promega). The TCR product was sequenced using
the ABI PRISM Big Dye termination reaction kit (Applied
Biosystems) and the sequences were defined according to the
international ImMunoGeneTics database (IMGT) TCR gene
nomenclature [65].
Generation of expression plasmids
The HLA-A*0201 (A2) a-chain and b2m sequences were
generated by PCR mutagenesis (Stratagene) and PCR cloning. All
sequences were confirmed by automated DNA sequencing. A
disulphide-linked construct was used to produce the soluble
domains (variable and constant) for both the TCR a- and b-
chains [66,67]. The soluble A2 a-chain (a-1, a-2 and a-3 domains)
was tagged with a biotinylation sequence. All 4 constructs, TCRa,
TCRb, A2-tagged and b2m, were inserted into separate pGMT7
expression plasmids under the control of the T7 promoter [66].
Protein expression, refolding and purification
Competent Rosetta DE3 E.coli cells were used to express the
TCRa, TCRb, A2-tagged and b2m proteins in the form of
inclusion bodies (IBs) as described previously [66]. For a 1L TCR
refold, 30 mg of AS01 a-chain IBs were incubated at 37uC for
15 mins with 10 mM DTT and added to cold refold buffer
(50 mM TRIS pH 8.1, 2 mM EDTA, 2.5 M urea, 6 mM
cysteamine hydrochloride and 4 mM cystamine). After 15 mins,
30 mg of AS01 b-chain, incubated for 15 mins at 37uC with
10 mM DTT, was added. For a 1 L GLC-A2 refold, 30 mg of A2
a-chain was mixed with 30 mg of b2m and 4 mg of the
GLCTLVAML peptide (or GLC mutants) for 15 mins at 37uC
with 10 mM DTT. This mixture was then added to cold refold
buffer (50 mM TRIS pH 8, 2 mM EDTA, 400 mM L-arginine,
6 mM cysteamine hydrochloride and 4 mM cystamine). Refolds
were mixed at 4uC for 1 hr. Dialysis was carried out against
10 mM TRIS pH 8.1 until the conductivity of the refolds was
under 2 mS/cm. The refolds were then filtered and purified.
Primary purification was conducted using an ion exchange
(Poros50HQTM) column and secondary purification was con-
ducted using a gel filtration (Superdex200HRTM) column. The
protein was purified using either BIAcore buffer (10 mM HEPES
pH 7.4, 150 mM NaCl, 3 mM EDTA and 0.005% (v/v)
Surfactant P20) or crystallization buffer (10 mM TRIS pH 8.1,
10 mM NaCl). Protein quality was analyzed by Coomassie-stained
SDS-PAGE.
SPR analysis
Binding analysis was performed independently using a BIAcore
3000 and a BIAcore T100 equipped with a CM5 sensor chip as
reported previously [68]. Between 200 and 400 response units
(RUs) of biotinylated pMHC was immobilized to streptavidin,
which was chemically linked to the chip surface. The pMHC was
injected at a slow flow rate (10 ml/min) to ensure uniform
distribution on the chip surface. Combined with the small amount
of pMHC bound to the chip surface, this reduced the likelihood of
off-rate limiting mass transfer effects. AS01 TCR was concentrated
to 100 mM on the same day of SPR analysis to reduce the
likelihood of TCR aggregation affecting the results. For equilib-
rium and kinetic analysis, ten serial dilutions were carefully
prepared in triplicate for each sample and injected over the
relevant sensor chips at 25uC. AS01 was injected over the chip
surface using kinetic injections at a flow rate of 45 ml/min. For
thermodynamic experiments, this method was repeated at the
following temperatures: 12uC, 19uC, 25uC, 32uC, and 37uC.
Results were analyzed using BIAevaluation 3.1, Microsoft Excel
and Origin 6.1. The equilibrium binding constant (KD) values
were calculated using a nonlinear curve fit (y=( P 1x)/(P2 + x)). The
thermodynamic parameters were calculated according to the
Gibbs-Helmholtz equation (DGu=DH 2 TDSu). The binding free
energies, DGu (DGu=-RTlnKD) were plotted against temperature
(K) using nonlinear regression to fit the three-parameter equation,
(y=dH+dCp*(x-298)-x*dS-x*dCp*ln(x/298)), as reported previ-
ously [69].
Simulation of V(D)J recombination
The process of convergent recombination encompasses the
production of an amino acid sequence by a variety of nucleotide
sequences and the production of a nucleotide sequence by a
variety of recombination mechanisms (i.e. different germline gene
contributions and nucleotide additions) [17,29,30,31]. It also
accounts for the frequent occurrence of some V(D)J recombination
events due to the involvement of fewer nucleotide additions. To
quantitatively assess the collective contribution of these various
elements of convergent recombination in enhancing the produc-
tion frequency of some TCR amino acid clonotypes relative to
others in the absence of recombination biases, we used computer
simulations of a random V(D)J recombination process [30] to
estimate the relative production frequencies of the observed GLC-
specific TCR amino acid clonotypes. The maximum number of
nucleotide deletions from the ends of the TCR genes and the
maximum number of nucleotide additions considered in the
simulations were chosen to allow for the production of the
majority of observed TCR sequences. For the TRAV5/TRAJ31
clonotypes, the simulated VJ recombination process allowed up to
10 nucleotide deletions from the 39 end of the TRAV5 gene, up to
16 deletions from the 59 end of the TRAJ31 gene, and up to 16
nucleotide additions. For each simulated TCR sequence, the
number of nucleotide deletions from the 39 end of the TRAV5
gene, the number of nucleotide deletions from the 59 end of the
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determined from uniform distributions of the numbers of
nucleotide deletions and additions. The nucleotide base of each
of the nucleotide additions was randomly chosen. A total of 10
million in-frame TRAV5/TRAJ31 sequences were simulated. The
computer simulations were performed using Matlab 7.9.0 (The
Mathworks, Natick, MA).
Crystallization, diffraction data collection and model
refinement
AS01-GLC-A2 crystals were grown at 18uC by vapour diffusion
via the hanging drop technique. 200 nL of 1:1 molar ratio TCR
and pMHC-I (at 10 mg/ml) was added to 200 nL of reservoir
solution. Optimal crystals were obtained with 0.16 M calcium
acetate hydrate, 0.08 M sodium cacodylate pH 6.0, 12.5%
polyethylene glycol (PEG) 8000 and 20% glycerol. Data were
collected at 100 K on beamline IO3 at the Diamond Light Source
(DLS), Oxfordshire, UK. The AS01-GLC-A2 complex dataset
was collected at a wavelength of 0.976A ˚ using an ADSC Q315
CCD detector. Reflection intensities were estimated with the
MOSFLM package [70] and the data were scaled, reduced and
analyzed with SCALA and the CCP4 package [28]. The structure
was solved with Molecular Replacement using AMORE [71] .
The model sequence was adjusted with COOT [72] and the
model refined with REFMAC5 [73]. Graphical representations
were prepared with PYMOL [74]. Data reduction and refinement
statistics are shown in Table 1. The reflection data and final model
coordinates were deposited with the PDB database, assigned
accession code 3O4L.
Supporting Information
Figure S1 Panels A-F show raw data for the equilibrium binding
analysis of the A2-GLC specific AS01 TCR at 5, 12, 19, 25, 32
and 37uC. The AS01 TCR was injected over a CM5 sensor chip
with a negative control ligand immobilized on flow cell 1 (HLA-
A*0201 in complex with ALAAAAAAV peptide) and the ligand
under investigation immobilized on flow cell 2 (HLA-A*0201 in
complex with GLCTLVAML peptide). The response unit increase
observed during injection of the AS01 TCR over the control
surface on flow cell 1 can be observed as the smaller response unit
increase for each injection. The AS01 TCR was injected at the
following concentrations; 0.1, 0.1, 0.3, 0.6, 1.1, 2.4, 4.5, 9.1, 18.1,
36.2 and 72.4 mM. The increase in the concentration of these
injections can be observed by a larger increase in response units for
each injection from left to right. All data were performed in
triplicate. Representative data are shown.
Found at: doi:10.1371/journal.ppat.1001198.s001 (0.34 MB TIF)
Figure S2 Panels A-F show raw data for the equilibrium binding
analysis of the A2-GLC specific AS01 TCR to the alanine
substituted peptide variants. The AS01 TCR was injected over a
CM5 sensor chip with a negative control ligand immobilized on
flow cell 1 (HLA-A*0201 in complex with ALAAAAAAV peptide)
and the ligand under investigation immobilized on flow cell 2
(HLA-A*0201 in complex with GLCTLVAML peptide, or an
alanine substituted variant). The response unit increase observed
during injection of the AS01 TCR over the control surface on flow
cell 1 can be observed as the smaller response unit increase for
each injection. The AS01 TCR was injected at the following
concentrations; 0.3, 0.3, 0.7, 1.4, 2.8, 5.6, 11.1, 22.2, 44.5, 88.9
and 177.8 mM. The increase in the concentration of these
injections can be observed by a larger increase in response units
for each injection from left to right. All data were performed in
triplicate. Representative data are shown.
Found at: doi:10.1371/journal.ppat.1001198.s002 (0.33 MB TIF)
Figure S3 The thermodynamic parameters of the A2-GLC
specific AS01 TCR at 37uC werecalculated accordingto the Gibbs-
Helmholtz equation (DGu = DH 2 TDSu). The binding free
energies, DGu (DGu = -RTlnKD), were plotted against tempera-
ture (K) using nonlinear regression to fit the three-parameter
equation, (y=dH+dCp*(x-298)-x*dS-x*dCp*ln(x/298)), as previ-
ously reported [24].
Found at: doi:10.1371/journal.ppat.1001198.s003 (0.79 MB TIF)
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